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Type 1 diabetes is one of the classical examples of or-
gan-specific autoimmune diseases characterized by lympho-
cytic infiltration or inflammation in pancreatic islets called 
‘insulitis’. In contrast, type 2 diabetes has been traditionally 
regarded as a metabolic disorder with a pathogenesis that is 
totally different from that of type 1 diabetes. However, re-
cent investigation has revealed contribution of chronic in-
flammation in the pathogenesis of type 2 diabetes. In addi-
tion to type 2 diabetes, the role of chronic inflammation is be-
ing appreciated in a wide variety of metabolic disorders such 
as obesity, metabolic syndrome, and atherosclerosis. In this 
review, we will cover the role of innate immunity in the patho-
genesis of metabolic disorders with an emphasis on NLRP3.
[Immune Network 2011;11(2):95-99]
INTRODUCTION
Researches on inflammation have been greatly facilitated by 
the  discovery  and  characterization  of  innate  immune  re-
ceptors such as TLR, NLR, RLR or CLR. Role of TLR, the first 
immune receptor characterized, in type 2 diabetes, obesity or 
atherosclerosis has been suggested in several previous papers 
(1,2) which can explain chronic inflammation in type 2 dia-
betes  (3,4).  In  contrast,  the  role  for  NLR  in  metabolic  dis-
orders is being recognized only recently. Among NLRs com-
prising more than 20 members, NLRP family members may 
be particularly relevant for metabolic disorders because NLRP, 
as  a  constituent  of  inflammasome,  plays  a  vital  role  in  the 
maturation  and  release  of  IL-1β (5).  IL-1β has  been  im-
p l i c a t e d  i n  b o t h  t y p e  1  a n d  t y p e  2  d i a b e t e s  ( 6 - 8 ) ,  a n d  i n -
flammasome is an essential component of the intracellular ma-
chinery  for  IL-1β  induction  and  maturation  in  response  to 
exogenous  or  endogenous  stimuli  (“danger  signal”)  (9).
NLRP3 AS A SENSOR OF “DANGER SIGNAL”
Activation of NLRP has been intensely investigated. However, 
certain steps of NLRP activation are not clearly understood. 
After contact with DAMP (death-associated molecular pattern) 
or  PAMP  (pathogen-associated  molecular  pattern),  NLRP 
self-oligomerizes through NACHT domain to form a high-mo-
lecular weight flatform. In the case of NLRP2 or NLRP3, they 
bind to an adaptor protein called ASC which has both PYD 
domain  and  CARD  domain,  and  sometimes  is  also  called 
PYCARD. Upon stimulation, PYD domain of NLRP2 or 3 asso-
ciates with PYD domain of ASC through another homotypic 
interaction.  Then,  CARD  domain  of  ASC  entices  CARD  do-
main of procaspase-1. Homotypic clustering of procaspase-1 
induces self-cleavage of the ‘pro’ domain and formation of 
the active caspase-1 p10/p20 tetramer, which then processes 
pro-IL-1β to IL-1β by cleavage of another ‘pro’ sequence 
( 1 0 )  ( F i g .  1 ) .  W h i l e  t h e  m o l e c u l a r  m e c h a n i s m  d o w n s t r e a m 
of NLRP oligomerization is well characterized, intracellular se-
quence  leading  to  oligomerization  of  NLRP  remains  to  be 
elucidated.  Cytosolic  delivery  of  PAMP  through  pannexin-1 
hemichannel interacting with P2X7 ATP receptor, K
＋ efflux, 
lysosomal injury and reactive oxygen species (ROS) formation 
have been implicated as the proximal events leading to NLRP 
oligomerization  (10,11)  (Fig.  1).  Recent  papers  have  pre-
sented  evidence  suggesting  the  role  of  mitochondria  as  a Role of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes
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Figure 1. Pathway for NLRP3 activation. As there is no evidence of direct physical contact between ligands and NLRP3, three major pathways 
for NLRP3 activation have been proposed such as direct cytoplasmic delivery of bacterial ligands through pannexin-1 hemichannel, ROS 
production, and lysosomal injury by crystalline/particulate ligands such as cholesterol crystal or monosodium urate.
source of ROS leading to NLRP stimulation (12,13). A recent 
paper claimed the role of ROS in the dissociation of TXNIP 
from  thioredoxin  leading  to  its  binding  to  NLRP3  and  in-
flammasome activation (14). An interesting point in the rela-
tionship between inflammasome and metabolism is that gly-
buride, a well-known  drug of  sulfonylurea class for type 2 
diabetes inhibits NLRP3 stimulation, which is independent of 
its  effect  on  ATP-sensitive  KATP c h a n n e l  ( 1 5 ) .  E f f e c t  o f  g l y-
buride on sepsis has also been reported. Considering the pro-
posed role of NLRP3 activation in type 2 diabetes and meta-
bolic syndrome (see below), it will be an intriguing question 
how  much  of  the  effect  of  glyburide  on  type  2  diabetes 
would be explained by NLRP3 inhibition. While the role for 
NLRP3  is  most  prominent  in  the  development  of  in-
flammation,  its  role  in  the  protection  of  epithelial  cells  has 
also been demonstrated (16), which is reminiscent of the pre-
viously reported role of TLR in the protection of intestinal epi-
thelial  cells  (17).
NLRP3 AND INSULIN RESISTANCE
Several  papers  have  implicated  diverse  arms  of  innate  im-
munity such as TLR, eosinophils or mast cells in insulin resist-
ance  (4,18,19).  A  recent  paper  reported  the  role  of  NLRP3 
in  obesity-induced  inflammation  and  insulin  resistance.  In 
that  paper,  positive  correlation  between  IL-1β (or  NLRP3) Role of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes
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mRNA expression and body weight of calorie-restricted mice 
was shown. Improved glucose tolerance was also found in 
obese mice with targeted disruption of NLRP3. IL-1β release 
in response to ceramide in conjunction with LPS was also ab-
rogated  in  NLRP3-knockout  macrophages  (20).  However,  it 
is still not clear if C2 ceramide used in that experiment could 
represent  lipids  associated  with  obesity  in  vivo.  It  also  re-
mains to be clarified what lipid intermediates or metabolites 
are  able  to  activate  inflammasome  in  obese  subjects.
NLRL3 AND PANCREATIC ISLET CELLS
A recent paper reported the expression of NLRP3, ASC and 
caspase-1 in islet cells. Decreased IL-1β release from NLRP3- 
knock out islet cells was also shown. NLRP3-knockout mice 
showed  improved  glucose  profile  after  high-fat  diet,  which 
was ascribed to the attenuated IL-1β release from islet cells 
of NLRP3-knockout mice (14). Hyperglycemia-induced IL-1β 
release was also ascribed to increased ROS in response to hy-
perglycemia,  induction  of  TXNIP  and  subsequent  activation 
of NLRP3. However, it is not clear whether the source of IL-1β 
from islet cells is β-cells or immune cells in islets such as 
macrophages. Altered glucose metabolism in TXNIP-knockout 
mice might be also due to causes other than NLRP3 activation 
(21).
    A recent report showed activation of NLRP3 by islet amy-
loid  polypeptide  (IAPP).  Human  diabetes  and  murine  dia-
betes differ from each other in several points. One of the fun-
damental differences between them is frequent deposition of 
amyloid in islets of human type 2 diabetes but not in those 
of murine diabetes. Such a difference is due to the difference 
in  amino  acid  sequence  of  IAPP.  Human  IAPP,  the  major 
component of islet amyloid, is amyloidogenic while murine 
one is not, which is attributable to the difference in their ami-
no  acid  sequences.  Masters  et  al.  showed  that  human-type 
IAPP is able to induce NLRP3 activation and IL-1β release 
from dendritic cells or macrophages primed with LPS or mini-
mally modified LDL (mmLDL), an agonist for TLR4 (22). Such 
results  are  similar  to  the  activation  of  NLRP3  of  microglial 
cells by amyloid-β via lysosomal injury (23); however, the 
role  of  TXNIP  was  not  evident  in  IAPP-induced  NLRP3 
activation.
NLRP3 IN OTHER TYPES OF METABOLIC 
DISORDERS
Atherosclerosis  is  also  a  well-known  metabolic  disease  that 
has  prominent  inflammatory  features.  Role  of  innate  im-
munity in the pathogenesis of atherosclerosis has been dem-
onstrated  in  several  TLR-  or  MyD88-knockout  animals  (3). 
Recent papers showed the role of NLRP3 activation by choles-
terol crystals in the development of atherosclerosis (24) (Fig. 
1). Lysosomal injury after phagocytosis of cholesterol crystals 
appears  to  be  responsible  for  the  activation  of  NLRP3. 
Besides cholesterol crystal, the role for mmLDL crystal in the 
priming of cells for NLRP3 activation was also suggested. In 
t h a t  c a s e ,  m m L D L  m a y  b e  a b l e  t o  a c t  a s  b o t h  s i g n a l  1  
(priming signal) and signal for NLRP3 activation (24). Gout 
is  also  one  of  the  classical  examples  related  to  NLRP3 
activation. Gout is, in fact, one of the first metabolic diseases 
that  involve  activation  of  inflammasome.  Crystals  of  mono-
sodium  urate  and  calcium  pyrophosphate  dehydrate  were 
identified as the signals that are capable of NLRP3 activation 
in  gout  and  pseudogout,  respectively  (25)  (Fig.  1).
ROLF OF INNATE IMMUNITY IN TYPE 1 DIABETES
Type 1 diabetes is a well-known autoimmune disease that is 
characterized by a specific adaptive immunity against β-cell 
a n t i g e n s .  H o w e v e r ,  i n n a t e  i m m u n i t y  p l a y s  a  c r u c i a l  r o l e  i n 
the establishment of specific B- and T-cell immunity and its 
maintenance (26,27). We have reported that TLR, particularly 
T LR2 ,  pla ys  a  c ri ti ca l ro le  i n t he  pri mi ng  o f naïve  diabeto-
genic T cells in the pancreatic lymph nodes by sensing β-cell 
death  (28)  that  occurs  physiologically  during  the  organo-
genesis of the pancreas (27). A recent study also showed pos-
sible role of innate immunity other than TLR in the develop-
ment of type 1 diabetes by demonstrating the development 
of type 1 diabetes in MyD88-knockout NOD mice when they 
were rendered germ-free (29). However, it is not clear which 
types of innate immune receptors are involved in the devel-
opment of autoimmunity in those MyD88-knockout mice. It 
is also not known which types of innate immunity play roles 
in the apparent disease inhibition by intestinal microbiota in 
those mice. The role for NLRP3 or NLR has not been demon-
strated in the pathogenesis of type 1 diabetes. Further studies 
will  be  necessary  to  understand  the  disease-promoting  or 
-inhibitory  activity  of  NLR  in  type  1  diabetes.Role of Innate Immunity in Diabetes and Metabolism: Recent Progress in the Study of Inflammasomes
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CONCLUSION
Pathogenetic role of innate immunity is being generally ap-
preciated in diabetes and metabolism that had been consid-
ered as pure metabolic disorders. TLR was the first innate im-
mune  receptors  that  have  been  studied  in  those  diseases. 
Recent studies have shown important roles of non-TLR innate 
immune  receptors,  particularly  NLRP3  in  diverse  metabolic 
disorders such as diabetes, atherosclerosis, obesity and gout. 
Further studies will be necessary to identify endogenous or 
exogenous ligands or activating signals for innate immune re-
ceptors involved in the pathogenesis of such diseases and to 
develop therapeutic agents based on the novel immunological 
principles. 
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